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Risk factors for dialysis-associated hepatitis C in Venezuela. Utilizing
the first and second generation of enzyme immunoassays which detect
antibodies to the C virus we investigated the frequency of anti-HCV
antibodies in 315 patients undergoing hemodialysis. Other subpopula-
tions at risk were used as reference groups. One hundred and twenty-
three samples (39%) from the hemodialysis group repeatedly showed
anti-HCV positive antibodies while only 19% and 1% were positive in
the reference groups. The rate of anti-HCV reactive patients correlated
with time on hemodialysis (< 1 year, 17%; Ito 5 years 43%; > 5 years,
64%; r = 0.94, P < 0.001) and with the number of blood transfusions (1
to 10, 40%; > 10, 76%; r = 0.97; P < 0.001). Length of time on
hemodialysis was shown to be the major risk factor in thirty-three
anti-HCV positive patients who had no previous record of blood
transfusions. Co-infection with HBV was demonstrated in 41% out of
123 anti-HCV reactive patients, and increased alanine aminotransferase
(ALT) activity was documented in this co-infected group. Our results
further extend the observations on the predisposing factors to HCV
spread in hemodialysis units, and suggest that in these renal patients
co-infection with C and B viruses is a major cause of rising ALT
activity.
Infection with hepatitis C virus (HCV) is currently recog-
nized by the discovery of serum anti-HCV antibodies [1, 2] in
patient's blood. The available data suggest that HCV is the
major etiologic agent of blood-borne nonA-nonB hepatitis [3,
41. Patients on long-term hemodialysis are considered to be a
population at risk for HCV infection, but the influence of
factors such as time on hemodialysis and multiple blood trans-
fusions seems to vary among developed countries [5—7]. To
identify characteristics of the predisposing factors of HCV
infection in other geographical areas, we assessed the epidemi-
ological pattern of the HCV prevalence in eight Venezuelan
urban hemodialysis units, simultaneously exploring reference
groups having a high risk to HCV exposure.
Methods
Study subjects included 315 patients undergoing chronic
hemodialysis in eight units located at different hospitals in
Caracas, Venezuela. There were 184 men, (mean age 46 years,
range 17 to 87) and 131 women, (mean age 44 years, range 16 to
82). At the time of the study all patients were treated without
re-use of hemodialysis filters or blood lines. Several types of
artificial kidneys were used in the different units (Gambro
AK1O, Sweden; Monitral, Hospal Laboratories, Italy; SPS 450,
Cobe Travenol Lab, USA). Disinfection techniques were also
similar including the chemical sterilization procedure (8% so-
dium hypochiorite) for 35 minutes between each hemodialysis
period, or the use of a 2% aqueous glutaraldehyde solution and
heating (80C) during the same period of time, depending upon
the machine type. None of the patients had a history of
intravenous drug abuse and their socio-economic level was
essentially similar. A retrospective analysis of the clinical
record assessment of each patient was done to determine length
of time on chronic hemodialysis, the number of transfusion
units received, hepatitis B virus markers profile, and past and
recent alanine aminotransferase (ALT) values.
Anti-HCV antibodies were screened twice using the first and
second generation enzyme immunoassay developed by Abbott
Laboratories (North Chicago, Illinois, USA). The first genera-
tion HCV-EIA detects circulating anti-HCV antibodies to the
recombinant protein C-100-3 from the C virus, while the second
generation HCV-EIA detects antibodies from two additional
inmunogenic regions from the HCV genome named 33c and the
core [2]. The specificity and sensitivity of the currently avail-
able tests for anti-HCV antibodies are not well defined [81.
Therefore, only the repeatedly reactive samples were consid-
ered as positive for anti-HCV antibodies. Previous experience
employing one of these assays to screen 500 volunteer blood
donors [9] was extended by simultaneously testing 100 homo-
sexual men infected with human immunodeficiency virus
(HIV). As a reference group, we also included 27 serum
samples from patients with the diagnosis of nonA-nonB hepa-
titis obtained after ruling out HAY, HBV and Epstein-Barr
virus infections.
Statistical analysis
Statistical analysis was performed by the correlation coeffi-
cient test and by the x2 test using 2 x 2 and 3 X 3 distribution
tables.
Results
Prevalence of anti-HCV antibodies in hemodialysis patients
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When the 315 serum samples were assayed by the first
generation HCV-EIA, 124 samples were reactive. This group of
HCV positive samples was screened twice by the second
generation HCV-EIA and only one sample showed negative
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Table 1. Correlation between different variables (time on hemodialysis, blood transfusion record) and prevalence of anti-HCV positive
patients
Number of transfusions
Time on hemodialysis
<1 year 1—5 years >5 years
N N (2 0.9) N (6.8 I)
0 29 2 (7%) 71 25 (35%)b 12 6 (50%)C
1—10 36 9 (25%)d 132 56 (42%) 9 6 (67%f
>10 0 0 21 15(71%) 4 4(100%)
Abbreviations are N, number of serum samples; %, percentage of anti-HCV positive samples.
a vs. b vs. c, r = 0.88; P < 0.001
d vs. e vs. f, r = 0.98; P < 0.001
Table 2. HBV positive markers in anti-HCV positi
negative hemodialysis patients
ye and anti-HCV
Anti-HCV +
ye samples
HBV markers (N = 123)
Anti-HCV -
ye samples(N = 191)
HBsAg only 10 (8%)
Anti-HBs only 1 (0.8%)
Anti-HBc only 25 (20%)
HBsAg +Anti-HBc 11(9%)
Anti-HBs + Anti-H Bc 3 (2%)
Total 50 (4 1%)
15 (8%)
0
19 (10%)
7 (4%)
11(6%)
52 (27%)
Table 3. HCV and HBV markers in hemodialysis patients without
previous record of blood transfusions
Time on hemodialysis
<I year 1—5 years >5 years
Viral markers (29) (71) (12)
Anti-HCV 2 25 6
HBsAg only 0 1 0
Anti-HBs only 0 0 0
Anti-HBc only 0 3 0
HBsAg + Anti-HBc 0 0 3
Anti-HBs + Anti-HBc 0 1 0
results. Therefore, from the analysis of315 patients' serum, 123
(39%) were repeatedly reactive for anti-HCV antibodies. The
proportion of patients who were anti-HCV positive significantly
correlated with their length of time on hemodialysis (Table 1).
Similar results were observed upon comparison between the
transfusion record and the frequency of anti-HCV reactivity
(Table I). Correlation of both variables is depicted in Figure 1.
Moreover, analysis of results shown in Table I demonstrated
that 33 anti-HCV positive samples belonged to patients who
were on hemodialysis but who had no previous history of blood
transfusions. Twenty-five individuals from this subgroup of
patients were on hemodialysis between one and five years, six
had been dialyzed for more than five years and only two were
on hemodialysis for less than one year. We searched for the
possible specific source of contamination. None of the artificial
kidneys correlated with a significant number of anti-HCV
positive patients. Since this study represents the first HCV
screening practiced among Venezuelan hemodialysis patients,
typification and isolation of the HCV infected group were made
subsequently.
HBV markers associated with anti-HCV positive antibodies
Table 2 shows the results of the hepatitis B serology in the
subgroup of HCV positive patients. Fifty subjects (41%)
showed HBV markers plus anti-HCV antibodies. Fifty-two
(27%) patients from the group of 191 anti-HCV negative pa-
tients also demonstrated the presence of one or more HBV
markers. Table 2 divides both groups according to the identified
HBV profile.
Table 3 details the HBV marker's distribution within the
anti-HCV positive group who had no previous record of blood
transfusions. Only eight subjects demonstrated HBV markers.
As occurred with anti-HCV reactivity, all of those HBV posi-
tive patients fell in the subgroup of patients who were on
hemodialysis more than one year.
ALT activity, HBV markers and anli-HCV antibodies
Increased ALT values (twofold increase over the normal
upper limit) were documented in 65 (53%) out of 123 anti-HCV
positive patients. ALT values ranged between 80 and 888 lulL.
As depicted in Table 4, abnormal ALT activity was documented
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Fig. 1. Correlation between time on hemodia!ysis, number of blood
transfusions and prevalence of anii-HCV positive hemodia/ysis
patients.
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Table 4. Increased ALT activity and HBV markers in anti-HCV
positive and anti-HCV negative hemodialysis patients
Anti-HCV + Anti-HCV -
ye samples ye samples
Number of Number of
HVB markers samples ALT samples ALTb
HB5Ag only 10 3 15 7
Anti-HBs only 1 0 0 0
Anti-HBc only 25 12 19 1
HBsAg + Anti-HBc Il 5 7 2
Anti-HBSs + Anti-HBc 3 1 Ii 0
No HBV markers 73 44 139 29
Total 123 65 191 39
ALT two-fold increase over the normal upper limit.
a ALT ranges 80—888 LU/literb ALT ranges 76—523 LU/liter
more often in patients who had a coexistence of HCV plus HBV
infections than in patients with detectable HBV markers only.
So far, chronic persistent hepatitis, chronic active hepatitis and
active cirrhosis have been documented in a small number of the
HCV-only positive patients (data not shown). Liver biopsy is
currently planned for selected patients from both groups.
Reference groups
Samples from 5 of27 patients classified as having nonA-nonB
hepatitis repeatedly showed anti-HCV positivity. Three pa-
tients were characterized as having sporadic HCV infections
and two as having post-transfusional C hepatitis. As in our
previous report on Delta virus serological markers [10], anti-
HCV antibodies were only demonstrated in 1% of the HIV-
infected homosexual population.
Discussion
NonA-nonB hepatitis is increasingly recognized as a hazard
to patients undergoing hemodialysis [11, 12]. The availability of
tests which detect antibodies from a nonA-nonB virus desig-
nated as HCV has allowed the assessment of the impact of this
infection in different at-risk populations [3, 5—7]. In our inves-
tigation, we found that the prevalence of anti-HCV reactivity in
hemodialysis patients was two to three times higher than the
reported rates in some developed countries [5—7, 13]. There was
an association between the number of blood transfusions and
the frequency of anti-HCV reactive patients. Furthermore, the
presence of anti-HCV antibodies was demonstrated even in
patients who received fewer than 10 blood units. This finding
differs from data reported in some developed countries where
the influence of the use and number of blood transfusions or
blood products on the rate of HCV positive hemodialysis
patients has not been clearly established [6, 7, 14, 15]. At
present, we are not able to fully estimate the real incidence of
post-transfusional nonA-nonB hepatitis in different Venezuelan
populations including renal patients. However, screening of
Venezuelan volunteer blood donors has demonstrated a 1.2%
prevalence of anti-HCV positive carriers [9], which is similar to
that reported in Japan where typical post-transfusional nonA-
nonB hepatitis induced by reception of anti-HCV positive blood
units has been characterized [16]. This prevalence (1.2%) is also
similar to the reported rate of HBV surface antigen in Venezu-
ela, which is classified as a country with an intermediate rate of
HBV chronic carriers [10, 17, 18]. Moreover, thus far, Vene-
zuela has not implemented the ALT and anticore antibodies
screening at their blood banks, strategies which have demon-
strated to be cost effective in preventing up to 30% of post-
transfusion nonA-nonB hepatitis in developed countries [19—
22]. All these factors taken together support the association
demonstrated between the number of blood transfusions and
the rate of HCV infection found in Venezuelan hemodialysis
units.
There was an important proportion of patients who were
positive for anti-HCV antibodies and who were without a
history of blood transfusions. This group only showed the
length of time on hemodialysis treatment as the main risk
factor, which also significantly correlated with the frequency of
anti-HCV positivity in the whole group. Except for hemodial-
ysis, we were not able to identify a specific route of transmis-
sion for those patients. The observation that long-term hemo-
dialysis plays a major role for HCV infections is similar to
reports from Japan, Germany and Italy [13—15, 23]. As occurs
with HBV, factors associated with hemodialysis procedures
might be implicated in the high rate of HCV infection [6, 11,24].
In fact, in contrast with reports from other countries [5, 6, 23],
we found that an important proportion of the HCV-infected
hemodialysis group was also infected with HBV. Furthermore,
abnormal ALT activity was mainly demonstrated in this coin-
fected group and in patients infected only with HCV. In
addition to being a marker of inflammatory liver disease,
increased levels of alanine aminotransferase indicate HCV
infection [25]. Studies of hepatitis C viral sequences have
suggested that patients with positive anti-C-100-3 antibodies
and chronic nonA-nonB hepatitis probably are in a viremic state
[26]. Therefore, those hemodialysis patients with associated
anti-HCV antibodies and increased ALT activity are likely to be
potentially infectious, and therefore contribute to maintaining
the reservoir of HCV infection in renal care units.
At present, specific measures to control the spread of HCV
have been taken in Venezuelan blood banks and hemodialysis
units. For instance, very recently HCV screening has been
introduced in blood banks; in the renal care setting patients are
being tested for anti-HCV antibodies prior to entering hemodi-
alysis programs, and patients who test positive have been
separated from non-infected individuals. The long-term fol-
low-up should better determine the influence of the hemodial-
ysis procedure on the rate of HCV infection observed in
Venezuela.
Our results add further geographical evidence indicating that
blood transfusion and chronic hemodialysis are the primary
predisposing factors to the spread of HCV in renal patients.
HCV and HBV co-infection is a major cause of raised ALT
activity in Venezuelan hemodialysis patients.
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